Kornimate/medical-research-clean huggingface dataset:
quantitative detection of cea mrna in the smog and tissue exudate whole process collected during laparoscopic (robotic) radical gastrectomy in gastric cancer patients

Conditions: Gastric Cancer

Summary: the purpose of this smog 01 study is to observe the possibility of intraperitoneal dissemination of tumor cells throughout the entire laparoscopic (robotic) radical gastrectomy for gastric cancer and explore its related mechanisms and potential clinical significance with peritoneal metastasis.

cytological examination of peritoneal lavage fluid has become an important parameter for pathological staging and prognosis judgment of gastric cancer. however, the vast majority of previous studies have only focused on collecting peritoneal lavage fluid through laparotomy or laparoscopic exploration for cytological and tumor marker monitoring as further tumor staging. unfortunately, there is no research focusing on whether laparoscopic (or robotic) surgery under the carbon dioxide pneumoperitoneum environment can cause the iatrogenic spread of cancer cells, and there is also a lack of a practical and feasible method to collect smog and tissue exudates generated throughout the entire surgical process for cytological monitoring, to determine whether laparoscopic surgery itself may cause the iatrogenic spread of tumor cell, to uncover the potential mechanisms and propose appropriate preventive measures of peritoneal metastasis. therefore, the investigators have designed a special device to collect smog and tissue exudates generated during laparoscopic or robotic radical gastrectomy to determine whether there is a possibility of iatrogenic cancer cell dissemination in the abdominal cavity throughout the entire course of laparoscopic or robotic surgery by using rt-pcr to detect cea mrna, which can become one of the reasons for gastric cancer peritoneal metastasis.

Eligibility criteria:
inclusion criteria: * gastric adenocarcinoma confirmed by preoperative pathology * endoscopic and ct/mri enhanced examination confirmed that ct1-4an0-3m0 has the possibility of resection * to undergo radical gastrectomy (laparoscopic or robotic) under general anesthesia+/- epidural anesthesia (carbon dioxide pneumoperitoneum) * willing and able to comply with the research protocol * reach a written consent agreement before registration, and fully realize the right to withdraw from the study at any time without any loss exclusion criteria: * urgent surgery is required due to tumor emergencies (such as bleeding, perforation, and obstruction) * extensive peritoneal metastasis can be seen during intraoperative exploration * other diseases requiring simultaneous surgery * patients with ascites * pregnancy

Keywords: advanced gastric cancer laparoscopic(robotic) gastrectomy rt-pcr cea free intraperitoneal tumor cells
n-acetylcysteine and arginine administration in diabetic patients

Conditions: Type 2 Diabetes Mellitus; Hypertension

Summary: it has been demonstrated that the nitric oxide production is reduced in type 2 diabetic patients and that cardiovascular complications represent 80% of the causes of death in these patients. as nitric oxide is able to reduce platelet aggregation, increase the relaxation of smooth muscle cells, and reduce plasminogen activator inhibitor-1 and endothelin, we hypothesized that nitric oxide deficiency is responsable for the cardiovascular disease in type 2 diabetes mellitus. arginine and n-acetylcysteine, precursor and enhancer of the nitric oxide synthesis respectively, are able to increase nitric oxide production. aim of the study is to evaluate the effect of arginine and n-acetylcysteine administration on arterial blood pressure and different metabolic parameters in patients with type 2 diabetes mellitus and hypertension. subjects and methods. 24 male subjects, randomly divided in two groups, will be studied. these subjects will undergo a treatment with arginine (1200 mg once a day) plus n-acetylcysteine (600 mg twice a day) or placebo for six months. basal and final evaluations include: * general examination * abpm (ambulatory blood pressure monitoring) * hba1c, total-cholesterol, hdl-cholesterol, ldl-cholesterol, oxidized ldls, triglycerides, reduced/oxidized glutathione ratio in red blood cells, nitrites/nitrates, asymmetrical and symmetrical dimethyl-arginine, nitrotyrosine, arginine, homocysteine, c-reactive protein, interleukin-6, tumor necrosis factor-α, intercellular and vascular-cell adhesion molecules, plasminogen activator inhibitor-1 and fibrinogen * the ultrasound assessment of the intima-media thickness after endothelium-dependent flow-mediated vasodilation of the brachial artery expected results. increase of nitric oxide production and reduction of arterial blood pressure and oxidative parameters.


Eligibility criteria:
inclusion criteria: * male subjects * age between 40 and 70 years * type 2 diabetes mellitus and hypertension * mean 24h arterial blood pressure after the wash-out period: systolic \>136mmhg and/or diastolic \>86 mmhh * written informed consent exclusion criteria: * female subjects * mean 24h arterial blood pressure after the wash-out period: systolic \>180 mmhg and/or diastolic \>110 mmhg * secondary hypertension * significative cardiovascular complications of diabetes * cancer or severe systemic, hepatic, pulmonary, cardiovascular or diseases * actual treatment with nitrates, acetylcysteine or arginine * acetylcysteine hypersensitivity * psychiatric disturbs, abuse of drugs or alcohol * low compliance * absence of written informed consent

Keywords: nitric oxide oxidative stress diabetes hypertension endothelial dysfunction
clinical practice guidelines versus decision-support for latent tuberculosis infection (ltbi) management

Conditions: Latent Tuberculosis

Summary: latent tuberculosis infection (ltbi) guidelines can be complex. ltbi-assist is a web-based interactive tool to navigate us ltbi clinical practice guidelines in a patient-centered format that may guide clinical decision making around latent tb care. the research goal is to determine the difference in reported confidence among trainees that are not experts in ltbi care. the investigators further aim to assess if access to the ltbi-assist tool improves clinical decision making in a series of simulated case scenarios containing guideline-derived, multiple choice items, as well as assess the efficiency in navigating the scenarios - measured by time to complete the survey. the investigators proposed a randomized study design, in which an electronic survey/questionnaire with 4 case scenarios consisting of 14 multiple choice questions. participants providing informed consent will be randomized to receiving access to either us centers for disease control (cdc)/national tuberculosis (tb) controllers association (ntca) guidelines or the ltbi-assist online tool. those in the experimental arm will further complete a 10 question system usability scale to assess usability of the ltbi-assist tool. all johns hopkins medical trainees and residents will be eligible to participate.


Eligibility criteria:
inclusion criteria: * student at johns hopkins school of medicine, or medical trainee at hopkins hospital or bayview program exclusion criteria: * none

Keywords: tuberculosis education
special drug-use surveillance for kesimpta for s.c. injection 20 mg pen

Conditions: Relapsing-remitting Multiple Sclerosis; Active Secondary Progressive Multiple Sclerosis

Summary: this study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using kesimpta for the labeled indication.

this is a primary data collection-based special drug-use surveillance to be conducted in accordance with the gpsp ordinance. observational period will last 24 months from the start of treatment with kesimpta.

Eligibility criteria:
inclusion criteria: 1. patients must provide written consent to cooperate in this study before the start of treatment with kesimpta 2. patients using kesimpta for the first time for the following indication indication: prevention of relapses and and prevention of physical disability progression in the following patients * relapsing-remitting ms * active spms exclusion criteria: 1. patients with a history of treatment with a drug containing the same ingredient as kesimpta (investigational drug or post-marketing clinical study drug) 2. patients with a history of hypersensitivity to any of the kesimpta ingredients

Keywords: kesimpta multiple sclerosis japan
efficacy of green tea buccal tablets in oral lichen planus

Conditions: Oral Lichen Planus

Summary: is topical application of green tea polyphenols buccal tablet more effective in treatment of patients with symptomatic oral lichen planus in comparison with topical application of corticosteroids and what is the most effective concentration of polyphenols

* each patient was informed about the detailed procedure, and educated about benefits of the treatment, the known side effects and follow-up appointments needed. after that, each subject participating in the study signed an informed written consent form. * subjects were given freedom to leave the study at any time when they need to. group a (experimental group) 200 mg green tea where patients in this group will receive a buccal tablet containing 200 mg of green tea extract which adheres to the buccal mucosa slowly releasing the polyphenoles along around 8 hours 2 times aday for four weeks. preparation of buccal tablets : mucoahesive buccal tablets is prepared by a direct compression procedure. various batches are prepared by varying the chitosan:drug ratio to identify the most effective formulation. the mucoadhesive drug/polymer mixture is prepared by homogeneous mixing of the drug with chitosan , secondary polymer, and d-mannitol, in a glass mortar for 15 min. then, mg stearate will be added and mixed for 5 min .the mixture is compressed using a tablet machine (type ek: o.erweka apparatus, frankfurt, germany) using flat-tip punches and dies with 8-mm-diameter. each tablet weighed 212 mg with a thickness of 3.1 mm.( darwish and elmeshad,2009) group b (experimental group) 300 mg green tea where patients in this group will receive a buccal tablet containing 300 mg of green tea extract which adheres to the buccal mucosa slowly releasing the polyphenoles along around 8 hours 2 times aday for four weeks. group c (control group) corticosteroid group: where patients are treated with topical corticosteroids 1 mg/g triamcinolone acetonide (kenacort-a orabase 20 g pomad: deva dermatological product,turkey) applied topically 4 times a day i.e. following each meal and at bed time for four weeks .

Eligibility criteria:
inclusion criteria: * symptomatic lesions. * olp lesions with the diagnosis confirmed both clinically and histopathologically. * clinical score higher than 3. * disease duration of more than 2 months. * absence of dysplasia in histological section exclusion criteria: * presence of any visible oral lesion other than olp. * pregnant or breast-feeding women, * immuno-deficiency diseases. * current malignancy or malignancy in history. * concomitant treatment potentially effective on olp within the previous 2 months such as antimalarial agents, retinoids, corticosteroids or immunosuppressive drugs. * severe or recurrent infections. * lichenoid reaction. * patients presents with skin lesions which may require systemic corticosteroid therapy.
bridge percutaneous nerve stimulation for cesarean delivery pain control

Conditions: Opioid-use Disorder; Pain, Postoperative

Summary: this is a randomized, placebo controlled and natural-history controlled trial to investigate the effectiveness of nss-2 bridge® for postpartum women with and without opioid use disorder (oud). the purpose of this pilot investigation is to establish feasibility/acceptability of the trial design.

this study is a randomized control trial with the following arms: 1) active device; 2) placebo device; 3) non-intervention (active control). the devices will be placed while women are still feeling pain relief from labor epidural analgesia (after delivering vaginally) or from spinal or epidural anesthesia (after delivering by cesarean). by applying the devices while women are still relatively pain-free, a preventative/pre-emptive approach to pain management in women at risk for severe postpartum pain is taken. the study will enroll women with and without oud and follow them for five days postpartum.

Eligibility criteria:
inclusion criteria: * pregnant * third trimester * cesarean delivery under neuraxial anesthesia * healthy, clean skin * 18 years or older exclusion criteria: * not fluent in english (surveys are validated in english language), unable to participate in informed consent discussions, or unable to give informed consent for any reason * unable to participate fully in all study procedures for any reason * cesarean delivery under general anesthesia * history of hemophilia * pacemakers or implantable electronic devices * history of psoriasis
acute bronchitis in korea:associated microorganisms and clnincal findings.

Conditions: Acute Bronchitis

Summary: the investigators hypothesized that acute bronchitis will be associated with various bacteria and viruses.

the investigators will investigate various bacteria and viruses from colleced specimens from patients with acute bronchitis, and also investigate an assoication of the miroorganims with clinical findings

Eligibility criteria:
inclusion criteria: * adults patients aged over 18 years. * patients who complain of recent sputum and cough. exclusion criteria: * patinets who took antibiotics within 7 days. * patinets whose symptoms last for \< 5 days. * patients who have definite cause of acute cough such as pneumonia, allergic rhinnits, sinusitis, gerd and drug. * immunocompromised patients.

Keywords: acute bronchitis, bacteria, virus, clinical symoptoms
metacognitive therapy for comorbid insomnia

Conditions: Secondary Insomnia

Summary: the purpose of this study is to determine the effect of meta-cognitive therapy for insomnia.

this study is a randomized controlled trial with 50 patients with a psychiatric disorder and insomnia. the patients will be randomized into two groups of 25 patients. the first group receives meta-cognitive therapy, whereas the second group will be assigned to a waiting list control.

Eligibility criteria:
inclusion criteria: * insomnia secondary to a primary psychiatric disorder exclusion criteria: * substance abuse, psychotic symptoms, suicidal intentions, severe organic disorder or psychiatric disorder where sleep restriction is not advised, organic sleep disorder.
efficacy study of cdp870 in subjects with chronic plaque psoriasis who are candidate for systemic therapy and/or phototherapy/photochemotherapy

Conditions: Chronic Plaque Psoriasis

Summary: a study to assess the safety and efficacy of 2 different doses of cdp870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.


Eligibility criteria:
inclusion criteria: * adult men and women \> 18 years * subjects with chronic plaque psoriasis stable for at least 3 months and moderate to severe for at least 6 months * subjects with psoriasis area and severity index (pasi) ≥ 12 and body surface area (bsa) ≥ 10 % * subjects were candidates for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy exclusion criteria: * subjects with an erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis * a history of chronic infection, recent serious or life-threatening infection (within six months, including herpes zoster), or any current sign or symptom that may indicate an infection (e.g. fever, cough); * white blood cell counts less than 4000/mm\^3 or more than 20000/mm\^3 * suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis) * systemic lupus * non respect of adequate wash out periods for treatments that might have an impact on the disease * any associated disease that could be impacted by the study treatment intake * any other condition, which in the investigator's judgment would make the subject unsuitable for inclusion in the study

Keywords: chronic plaque psoriasis, anti tnfα cdp870, cimzia
the combination effect of platelet-rich plasma and hyaluronic acid for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: although platelet rich plasma (prp) and hyaluronic acid (ha) are beneficial for osteoarthritis of knee (oa knee), the combined effect of prp with ha was not clear so far. hence, investigator assess a prospective randomized double-blind controlled trial.

patients with single or bilateral oa knee will be enrolled and randomized into intervention and control group. one dose of prp is applied into both groups. one week later, one dose of ha is injected in intervention group and one dose of normal saline is injected in control group. outcome measurements included visual analog scale (vas)、lequesne's severity index、western ontario and mcmaster universities osteoarthritis index (womac)、balance test (biodex) and analysis of synovial fluid at different follow-up frame (1st month, 3rd month, 6th month and 1 year after treatment).

Eligibility criteria:
inclusion criteria: 1. age between 50 to 75 y/o. 2. alert consciousness 3. symptom of knee osteoarthritis persist at least 6 months and stage i to iii scored by ahlbäck grading system 4. the pain score measured by vas at least 4 points exclusion criteria: 1. has received hyaluronic acid, prp or steroid injection within 6 months 2. has received nsaids or steroid within one week 3. tumor or metastasis surrounding the knee joint 4. has received total knee replacement, major surgery in knee, rheumatoid arthritis 5. patient who cant tolerance the balance test. 6. thrombocytopenia or coagulopathy

Keywords: platelet rich plasma osteoarthritis of knee hyaluronic acid
a study of language interpretation solutions for people with breast cancer

Conditions: Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III

Summary: the study will be conducted in 2 overlapping phases. in phase 1, there will be a 3-arm randomized controlled trial of remote simultaneous medical interpreting/rsmi (arm 1), versus remote consecutive medical interpreting/rcmi (arm 2) and versus remote consecutive video medical interpreting/rcvi (arm 3) in breast cancer outpatient clinical encounters with spanish- and mandarin-speaking patients with limited english proficiency/lep (stages ii and iii disease) and english- speaking providers (who do not speak spanish/mandarin). in phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.


Eligibility criteria:
inclusion criteria: phase i patients * age \>=18 years (per emr) * preferred language for healthcare is spanish or mandarin (per self-report) * limited english proficient; cannot speak english "very well" (per self-report) * diagnosis of stage i, ii, iii, or iv breast cancer (per emr) * will be visiting msk oncologist for the first or second appointment (per emr) * will be continuing medical oncology visits at msk (per emr) * agrees to be audio-recorded (per self-report) phase 1 providers * breast cancer provider who sees patients (e.g., breast oncologists, advanced practice providers, and/or nurses) * does not speak spanish and/or mandarin; providers who speak one language and not the other may participate (e.g., speaks spanish but not mandarin) (per self-report) * agrees to be audio-record (per self-report) phase 2 (clinic staff only; patient participants will be drawn from phase 1) * is a staff member who works/worked in one of the study clinic sites during the period of phase 1 rct study activities * agrees to be audio-recorded (per self-report) exclusion criteria: phase 1 patients * has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per emr, patient's care team, or study team) * presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per emr, patients, care team, or study team) phase i providers * none phase 2 (clinic staff only; phase 1 patient participants follow above criteria) * none

Keywords: breast cancer breast cancer stage ii breast cancer stage iii language interpretation spanish mandarin memorial sloan kettering cancer center 24-350
prognostic factors and oncological outcomes in laparoscopic liver resection for crlm

Conditions: Colorectal Cancer; Liver Metastases; Surgery

Summary: laparoscopic liver resection (llr) has gained acceptance as an effective treatment for colorectal liver metastases (crlm) in selected patients, providing similar oncologic outcomes compared to open liver resection (olr). a single-center retrospective analysis of a prospectively maintained database was performed. the primary aim of this study was to determine prognostic factors for the survival outcomes associated with llr for crlm.

llr was defined as pure llr, including conversions to olr. in case of missing data, additional details were retrieved from the individual patient file. data on patient demographics, timing of diagnosis, neoadjuvant chemotherapy (nac), tumor characteristics (both primary tumor and crlm), histopathology, molecular characteristics, operative technique (including classification into anatomically major/technically major/minor lr), intra- and postoperative course, adjuvant chemotherapy (ac) as well as oncological outcomes (os and dfs) were gathered and analyzed. postoperative complications were graded according to the clavien-dindo classification. complications were classified as major in case of clavien-dindo ≥ 3a.

Eligibility criteria:
inclusion criteria: * patients diagnosed with colorectal liver metastases * patients who received laparoscopic liver resection for colorectal liver metastases * patients who received the laparoscopic liver resection between september 2011 and mid-march 2020 exclusion criteria: * patients with contraindication for laparoscopic liver resection * refusal to participate in the study

Keywords: hepatopancreatobiliary laparoscopic liver resection colorectal liver metastasis